70+ StartX Med Innovators with Medical Breakthroughs for the Prevention, Diagnostics and Treatment of Coronavirus Mobilize Efforts to Fast-Track Public Health Needs During Pandemic.
Palo Alto, CA — March 18, 2020 — StartX, a non-profit startup community of more than 1500 Stanford faculty and alumni founders, announces the launch of its StartX Med COVID-19 Task Force and the mobilization of its industry-leading medical companies providing solutions for the prevention, diagnostics and treatment of the novel coronavirus. The group of leading scientists, physicians and professor entrepreneurs will collaborate on outreach to government agencies, regulatory bodies and healthcare systems in the interest of public health. Read more...
The New Crop of Impact Funding Opportunities Follows the Recent Launch of the StartX Med COVID-19 Task Force with the Mobilization of 70+ Stanford Alumni Scientists and Physicians Working on Critical Solutions for the Prevention, Diagnostics and Treatment of the Novel Coronavirus.
Palo Alto, CA — March 30, 2020 — StartX, a non-profit community of 1,500+ Stanford alumni and faculty entrepreneurs, has been perfecting the online demo day experience for the past four years and was fully prepared to present funding opportunities to its network of thousands of top VCs and Investors when the pandemic broke out. Since then, opportunities to fund companies that are making an incredible impact in combating the coronavirus have grown significantly with the mobilization of the StartX Med COVID-19 Task Force and StartX has extended the Online Demo Day for companies fundraising for their COVID-19 solutions. Read more...
Applications to protect healthcare professionals from COVID-19 transmission while providing care for patients. Our technology is being used to help protect caregivers as they work in epicenters of the global breakout.
COVID-19 patient messaging and education through part of an Actionable Reminders product as well as bulk messaging from Broadcast products.
Mon Ami is a loneliness solution for seniors. In light of COVID-19, we have had to cut back visits in senior living and nursing homes out of public health precaution. We are devising ways to maintain social connection while our vulnerable members are isolated.
Optimizing hospital operations. We are powering several health system command centers with actionable information around capacity (negative airflow rooms, ventilators etc.) and information on dischargeable patients.
Preventing the spread of Coronavirus in this pandemic by turning existing face masks (R95 and R99) into a P100 mask that blocks 100% of particles preventing infection.
Aromyx is developing olfactory receptor arrays in field-deployable disposable test kits. The technology is enabling sample-to-answer, noninvasive, fast, easy-to-operate and inexpensive tools for the detection of infectious diseases through exhaled breath analysis, suitable for rapid early diagnosis and mass population screening.
One of the leading causes of death of the coronavirus is sepsis with its associated antibiotic resistance. Avails is developing rapid, automated antibiotic susceptibility testing equipment to help fight sepsis and antibiotic resistance, reducing the turnaround time to antibiotic therapy from days to a few hours.
One of the major symptom of COVID-19 is Acute Respiratory Distress. BioSerenity offers a Medical Device to home monitor patients. The data is transmitted remotely to health care providers. BioSerenity provides the service if needed.
Deep 6 AI uses artificial intelligence on medical records to match patients with clinical trials better and faster. Deep 6 is helping researchers find the right patients for their COVID-19 trials and make up for lost time on important trials delayed by the COVID pandemic.
COVID-19 Physicians need a way to differentiate high acuity patients that need life-saving treatment from the 95% of patients that will get better on their own. Diagnose Early patented a test that can accurately and non-invasively predict the clinical course of each patient and therefore guide treatment.
Eko combines the electronic stethoscope and EKG with powerful software and is the first platform for mobile acoustic cardiac monitoring in clinic or remotely.
Enable makes ultrasensitive antibody assays for autoimmune and infectious disease and is working on doing testing of 320 samples/day with its CLIA-certified lab, staffing and high-throughput analyzers.
GenapSys is a leading DNA sequencing company to bring genetic testing for the masses. GenapSys low-cost, compact and accurate NGS platform can allow large scale surveillance study of viral evolution of SARS-Cov2 in a truly decentralized model. GenapSys has been developing COVID-19 next-gen. sequencing test on its distributed sequencers for surveillance or high throughput screening in various labs close to the sample origin.
Inflammatix is developing tests that can inform on the presence, type and severity of infections.The latter can be used to risk-stratify patients who need (vs those that don't need) more acute care.
Next generation of infectious disease testing. Disposable test kit to detect DNA and RNA of infectious diseases.
A preclinical imaging system based on magnetic particle imaging (MPI) that is used for cell therapy tracking and inflammation monitoring.
Built a customizable microfluidic platform that is capable of running complex molecular assays, like RT-PCR (technique for the Stanford COVID19 test), in a fully automated, low-cost, and handheld device.
COVID-19 rapid tests suitable for schools, large events, and ER rooms and takes only 10 minutes.
ProbiusDx is developing an assay technology for multiplexed detection of biomarkers in volume-constrained biological specimens, for disease pathophysiology studies and for discovery of novel therapeutics.
Accelerate the development of applications to study and cure cellular diseases.
Developing a handheld device that acquires multiple physiological signals in a single patient setting for managing cardiopulmonary health. Data acquired includes end temperature, lung sounds, airway pressure, pulmonary function, ECG, and SPO2.
Sandstone’s Torq Zero Delay Centrifuge System is readily deployable for remote sample collection and prep for point-of-care blood diagnostics and stabilizing samples specimens for shipment to centralized laboratories.
High Quality Data for Medical Research
Mobile Application to assess Covid19 symptoms and provide an initial evaluation in the case of a COVID19 infection and filtering out those who either have a regular flu or have asthma / allergic symptoms, in order to reduce the load on healthcare professionals.
COVID-19 quarantine management program for remotely monitoring quarantined patients and healthcare workers who have been exposed.
Spire Health is the leader in remote patient monitoring for respiratory diseases. Our clinically proven platform is already widely deployed in pulmonary/critical care practices. It can be used to remotely monitor the disease progression of COVID-19 patients or at-risk individuals. This will alleviate burden on potentially overtaxed in-patient care facilities.
Subtle Medical has 2 FDA-cleared AI software products for faster and low-dose imaging (PET-CT and MR). Studies find CT provides the best diagnosis for COVID-19.
APstem's cell therapy restores lung structure and function damaged by COVID-19.
Augmedix provides doctors with hardware, Smartphones or Google Glass, to securely stream the patient visit to its cloud-based platform. When the healthcare system is highly burdened, as it is right now with COVID-19, Augmedix provides the best opportunity to increase doctor productivity and patient access.
Our platform assists researchers in performing successful experiments, resulting in much faster discoveries. Bioz can help scientists accelerate the pace of finding a cure for COVID-19 and a vaccine against the SARS-CoV-2 virus.
Bright.md is offering a paired down version of our best of breed asynchronous care solution at no cost, in order to help manage the influx of activity during this crisis. This new COVID-19 screening tool can sit outside of SmartExam and be available as a widget on any healthcare system website or portal pages.
We build control systems for chimeric antigen receptor (CAR) T cell technology. Our technologies are designed to mediate adverse immune events in CAR T therapies which can be extended to address challenges that critically ill COVID-19 patients face.
Dr. Ruth Ann Crystal has crowd sourced a free online handbook for doctors around the world to share their knowledge on treating COVID19: https://buff.ly/335KYz0
Gauss Surgical, a med tech company, develops a mobile vision-based platform for accurate and real-time measurement of surgical blood loss.
GEn1E’s p38 kinase inhibitor drugs treat Acute Respiratory Distress Syndrome (ARDS) - 67% of the critically ill COVID-19 patients had ARDS. In addition, GEn1E drugs may have direct antiviral effects by boosting host-immune response..
Globavir’s drug GBV 006 - works at the host level - the common mechanisms that get hijacked by various viruses including dengue virus, ebola and coronavirsus. GBV 006 works virus entry into the cells as well as on various mechanisms that involve virus assembly in the cells.
Guided Clarity is launching a clinical nutrition for pulmonary critical care. It lowers infection-induced cytokine storm in lungs, with the potential to reduce ICU incidence and duration.
Dr. Michael Niaki is the Diagnostic Subgroup lead and advisor for the StartX Med COVID-19 Task Force.
KangarooHealth provides HIPAA-compliant solutions for coronavirus risk monitoring (enterprises and individuals): (1) an intelligent quarantine management solution for healthcare systems and employers to remotely track their people under investigation for coronavirus risks; (2) a FREE mobile application for individual patients to remotely monitor their health status and symptoms, detect important moments when escalation of care is needed, and connect them to healthcare professionals online for early triage. It reduces unnecessary ER visits and reduces cross contamination risks.
OMNY’s platform tracks both episodes of care for COVID-19 as well as the availability of both treatments and supplies, allowing for near real-time coordination of critical supplies across health systems and geographic locations.
We have a treg cell therapy.
We provide an exosome based liquid biopsy platform for precision molecular diagnostics of cancer patients.
Mesenchymal stem cells (MSC) are plentiful in fat and have anti-inflammatory and immune effects that may help patients with COVID-19 respiratory distress. Our device can quickly get high yields of these stem cells from a patient's fat for immediate use. We're gearing up for clinical trials with COVID-19 patients and are reaching out to hospitals at this time to help.
Teleon's messaging and broadcasting platform helps senior care providers communicate with patients and their families, coordinate care across distributed teams, and manage staffing and new admissions efficiently to respond to COVID-19.
Providing intelligent visualization of key clinical content to providers directly within their EHR workflow.
StartX is a nonprofit organization advancing the development of Stanford’s top entrepreneurs through experiential education, access to thousands of VCs and investors, and a Who’s Who of industry leaders and serial entrepreneurs providing mentorship. The founder community consists of a diverse mix of 1500+ well-funded Growth-Stage Founders, tenured Stanford Professor Founders, and highly-successful Stanford Alumni Founders. Collectively, StartX companies have raised $8 billion in funding with a combined valuation of more than $22 billion to date. StartX’s Corporate Innovation program helps global corporations quickly test market-ready technology from Stanford alumni founders through structured co-creation and pilot programs. Ranked as a number one accelerator nationally by MIT’s Seed Accelerator Rankings Project, StartX venture funded companies have a 93% survival and acquisition rate in a wide range of industries from consumer Internet and retail products to enterprise software, biotechnology and medical devices.
StartX and StartX Med, the medical entrepreneurial vertical of StartX, includes accomplished founders ranging from undergraduates and masters students to post docs, professors and Stanford alumni being mentored by top Silicon Valley industry leaders. For medical tech founders homegrown at Stanford’s School of Medicine, having intimate access to domain experts and care environments has been fundamental to their success. StartX Med entrepreneurial scientists are changing the world with medical breakthroughs and successful life-saving research trials, including an average of more than six FDA approvals per year. Clinical partners of StartX Med companies encompass more than 250 hospitals, 30,000 care centers, 50,000 physicians and 65 million annual patient visits. StartX Med founders also have the opportunity to utilize 2,000 square feet of shared wet lab space at the StartX facility, located down the street from Stanford University. StartX continues to be a unique startup community compared to accelerators and incubators and does not take equity in companies for admittance into its programs.